HPC2/ELAC2 polymorphisms and prostate cancer risk: Analysis by age of onset of disease

42Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The candidate prostate cancer susceptibility gene HPC2/ELAC2 has two common coding polymorphisms: (Ser → Leu 217) and (Ala → Thr 541). The Thr541 variant in the HPC2/ELAC2 gene has previously been reported to be at an increased frequency in prostate cancer cases. To evaluate this hypothesis we genotyped 432 prostate cancer patients (including 262 patients diagnosed ≤ 55 years) and 469 UK, population based control individuals with no family history of cancer. We found no significant difference in the frequencies of Thr541-containing genotypes between cases and controls (OR=1.41, 95% CI 0.79-2.50). The association remained non-significant when the analysis was restricted to cases divided by age of onset into those diagnosed ≤ 55 years (OR=1.50, 95% CI 0.79-2.85) or to patients diagnosed > 55 years (OR=1.27, 95% CI 0.59-2.74). We conclude that any association between the Thr541 variant and prostate cancer is likely to be weak. © 2002 Cancer Research UK.

Cite

CITATION STYLE

APA

Meitz, J. C., Edwards, S. M., Easton, D. F., Murkin, A., Ardern-Jones, A., Jackson, R. A., … Eeles, R. A. (2002). HPC2/ELAC2 polymorphisms and prostate cancer risk: Analysis by age of onset of disease. British Journal of Cancer, 87(8), 905–908. https://doi.org/10.1038/sj.bjc.6600564

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free